CU20230031A7 - Método para la detección de anticuerpos antifármaco contra anticuerpos de factor xi y/o factor xia - Google Patents

Método para la detección de anticuerpos antifármaco contra anticuerpos de factor xi y/o factor xia

Info

Publication number
CU20230031A7
CU20230031A7 CU2023000031A CU20230031A CU20230031A7 CU 20230031 A7 CU20230031 A7 CU 20230031A7 CU 2023000031 A CU2023000031 A CU 2023000031A CU 20230031 A CU20230031 A CU 20230031A CU 20230031 A7 CU20230031 A7 CU 20230031A7
Authority
CU
Cuba
Prior art keywords
factor
antibody
fxi
xia
detection
Prior art date
Application number
CU2023000031A
Other languages
English (en)
Spanish (es)
Inventor
Daniel M Bloomfield
Debra A Freedholm
Jonathan E Freeman
Royston J Glasspool
Yasser Khder
Original Assignee
Anthos Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anthos Therapeutics Inc filed Critical Anthos Therapeutics Inc
Publication of CU20230031A7 publication Critical patent/CU20230031A7/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G01N33/686—Anti-idiotype
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54306—Solid-phase reaction mechanisms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54393—Improving reaction conditions or stability, e.g. by coating or irradiation of surface, by reduction of non-specific binding, by promotion of specific binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96433—Serine endopeptidases (3.4.21)
    • G01N2333/96441—Serine endopeptidases (3.4.21) with definite EC number
    • G01N2333/96452—Factor XI (3.4.21.27)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CU2023000031A 2020-12-18 2021-12-17 Método para la detección de anticuerpos antifármaco contra anticuerpos de factor xi y/o factor xia CU20230031A7 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063127536P 2020-12-18 2020-12-18
PCT/US2021/064117 WO2022133263A1 (en) 2020-12-18 2021-12-17 Methods for the detection of anti-drug antibodies against factor xi and/or factor xia antibodies

Publications (1)

Publication Number Publication Date
CU20230031A7 true CU20230031A7 (es) 2024-02-07

Family

ID=82059801

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2023000031A CU20230031A7 (es) 2020-12-18 2021-12-17 Método para la detección de anticuerpos antifármaco contra anticuerpos de factor xi y/o factor xia

Country Status (19)

Country Link
US (1) US20240077497A1 (https=)
EP (1) EP4264278A4 (https=)
JP (1) JP2023554347A (https=)
KR (1) KR20230121120A (https=)
CN (1) CN116601491A (https=)
AR (1) AR124434A1 (https=)
AU (1) AU2021401421A1 (https=)
CA (1) CA3199482A1 (https=)
CL (1) CL2023001709A1 (https=)
CO (1) CO2023008150A2 (https=)
CR (1) CR20230313A (https=)
CU (1) CU20230031A7 (https=)
EC (1) ECSP23053645A (https=)
IL (1) IL302904A (https=)
JO (1) JOP20230137A1 (https=)
MX (1) MX2023007281A (https=)
PE (1) PE20231679A1 (https=)
TW (1) TW202242414A (https=)
WO (1) WO2022133263A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025523802A (ja) * 2022-07-13 2025-07-25 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 分析物を検出するための弱酸性免疫アッセイ

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY36751A (es) * 2015-06-26 2017-01-31 Novartis Ag Anticuerpos de factor xi y métodos de uso
EP3713965A1 (en) * 2017-11-22 2020-09-30 Novartis AG Reversal binding agents for anti-factor xi/xia antibodies and uses thereof
MX2020004921A (es) * 2017-11-29 2020-08-27 Hoffmann La Roche Ensayo de anticuerpo antifarmaco con supresion de interferencia del objetivo.
WO2020231992A1 (en) * 2019-05-13 2020-11-19 Regeneron Pharmaceuticals, Inc. Improved competitive ligand binding assays

Also Published As

Publication number Publication date
JOP20230137A1 (ar) 2023-06-14
ECSP23053645A (es) 2023-08-31
CL2023001709A1 (es) 2023-11-17
WO2022133263A1 (en) 2022-06-23
TW202242414A (zh) 2022-11-01
CR20230313A (es) 2023-08-18
AU2021401421A1 (en) 2023-06-22
US20240077497A1 (en) 2024-03-07
IL302904A (en) 2023-07-01
EP4264278A4 (en) 2024-11-27
AR124434A1 (es) 2023-03-29
AU2021401421A9 (en) 2024-10-24
EP4264278A1 (en) 2023-10-25
CA3199482A1 (en) 2022-06-23
JP2023554347A (ja) 2023-12-27
KR20230121120A (ko) 2023-08-17
CN116601491A (zh) 2023-08-15
MX2023007281A (es) 2023-09-04
CO2023008150A2 (es) 2023-06-30
PE20231679A1 (es) 2023-10-19

Similar Documents

Publication Publication Date Title
Rulander et al. Interference from anti-streptavidin antibody
RU2011141499A (ru) Способ определения пола птиц
NO20076662L (no) Deteksjon av et malantigen uavhengig av tilstedevaerelse eller fravaer av et korresponderende terapeutisk antistoff
MX2021005329A (es) Ensayos de luminiscencia no enzimaticos.
ATE532051T1 (de) Differenzielle reflexionsspektroskopieverfahren zur erkennung von sprengstoffen
WO2021046316A3 (en) Anti-drug antibody assay
CA2690718A1 (en) Device, kit and method for hookworm antigen capture and detection
EA202190237A1 (ru) Способы уменьшения мешающего влияния мишени лекарственного средства в иммунологическом анализе на антитела к лекарственному средству (ada)
CU20230031A7 (es) Método para la detección de anticuerpos antifármaco contra anticuerpos de factor xi y/o factor xia
Nabi et al. Seminal bacterial contaminations: Probable factor in unexplained recurrent pregnancy loss
MX2021010984A (es) Analizador de concentracion en el punto de atencion.
BR112018007842A2 (pt) imunoensaio para a detecção de cininogênio clivado de alto peso molecular, método, anticorpo isolado, kit para detectar um cininogênio de alto peso molecular clivado (hmwk)
MX357292B (es) Método para detectar cáncer.
CN102936501A (zh) 量子点-有机染料复合物关/开型镉离子比率荧光探针及其制备方法
Horn et al. Serological testing for SARS‐CoV‐2 antibodies in clinical practice: A comparative diagnostic accuracy study
US20150148249A1 (en) Method of improving the sensitivity of competitive immunoassay
Jiang et al. Simultaneous determination of gastric cancer biomarkers pepsinogen PGI/PGII using element tagged immunoassay coupled with inductively coupled plasma mass spectrometry detection
Pinder et al. Humoral and cellular responses to SARS‐CoV‐2 in patients with B‐cell haematological malignancies improve with successive vaccination
KR102659358B1 (ko) 유리 항원을 이용한 면역 검정법에서의 후크 효과 감지 방법
EA201400571A1 (ru) Специфичные к трансресвератролу антитела и их применение
CN108956573A (zh) 一种检测xiap蛋白的试剂盒及其应用
CN105004861A (zh) 一种人嗜铬蛋白a的免疫测定法及测定试剂盒
CA3080263A1 (en) Method for diagnosing cancer from blood
Kasetsirikul et al. A paper-based immunofluorescent device for the detection of SARS-CoV-2 humanized antibody
CN105842447A (zh) 一种针对乙肝表面抗原的检测方法